

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
07 February 2019 (07.02.2019)



(10) International Publication Number
WO 2019/025545 A1

(51) International Patent Classification:

C07K 16/10 (2006.01) **A61P 35/00** (2006.01)

C07K 16/28 (2006.01)

(21) International Application Number:

PCT/EP2018/071002

(22) International Filing Date:

02 August 2018 (02.08.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/EP2017/069839

04 August 2017 (04.08.2017) EP

PCT/EP2018/052946

06 February 2018 (06.02.2018) EP

(71) Applicants: **GENMAB A/S** [DK/DK]; Kalvebod Brygge 43, 1560 Copenhagen V (DK). **BIONTECH AG** [DE/DE]; An der Goldgrube 12, 55131 Mainz (DE).

(72) Inventors: **ALTINTAS, Isil**; c/o Genmab B.V. Uppsalalaan 15, 3584 CT Utrecht (NL). **SATIEN, David**; c/o Genmab B.V. Uppsalalaan 15, 3584 CT Utrecht (NL). **RADEMAKER, Rik**; c/o Genmab B.V. Uppsalalaan 15, 3584 CT Utrecht (NL). **PARREN, Paul**; Werdorperwaard 17, 3984 PR Odijk (NL). **SAHIN, Ugur**; c/o BioNTech AG An der Goldgrube 12, 55131 Mainz (DE). **GIESEKE, Friederike**; c/o BioNTech AG An der Goldgrube 12, 55131 Mainz (DE). **MUIK, Alexander**; c/o BioNTech AG An der Goldgrube 12, 55131 Mainz (DE). **GRUNWITZ, Christian**; c/o BioNTech AG, An der Goldgrube 12, Mainz, 55131 (DE).

(74) Agent: **GENMAB A/S**; Kalvebod Brygge 43, 1560 DK-Copenhagen V (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

WO 2019/025545 A1

(54) Title: BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF

(57) Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.